Ra Capital Management, L.P. - Jul 18, 2024 Form 4/A Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role
Director
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Stock symbol
CDTX
Transactions as of
Jul 18, 2024
Transactions value $
$0
Form type
4/A
Date filed
7/22/2024, 05:09 PM
Date Of Original Report
Jul 19, 2024
Previous filing
Jul 1, 2024
Next filing
Jul 24, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDTX Stock Option (right to buy) Award $0 +2.13K $0.00 2.13K Jul 18, 2024 Common Stock 2.13K $12.64 See Footnotes F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 19, 2024, the Reporting Person filed a Form 4 which inadvertently reported the exercise price of this stock option incorrectly.
F2 The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2025 annual meeting of stockholders.
F3 RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
F4 Laura Tadvalkar is a Managing Director of the Adviser who serves on the Issuer's board of directors. Under Dr. Tadvalkar's arrangement with the Adviser, Dr. Tadvalkar holds the option for the benefit of the Fund. Dr. Tadvalkar is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

Remarks:

Dr. Laura Tadvalkar, a Managing Director of the Adviser, serves on the Issuer's board of directors.